Connecticut doctors are part of new cancer trials: The goal? ‘Eradicate all deaths from breast cancer’Connecticut doctors are part of new cancer trials: The goal? ‘Eradicate all deaths from breast cancer’
About 170,000 women in the United States are living with metastatic breast cancer—or cancer that has spread to other organs—and eventually leads to death.
Hims & Hers Weight Loss Shots: What You Need To Know About The GLP-1s And Compounded DrugsHims & Hers Weight Loss Shots: What You Need To Know About The GLP-1s And Compounded Drugs
Post Content Post Content
First it was Ozempic. Now the peptide gold rush is here — and it’s dangerousFirst it was Ozempic. Now the peptide gold rush is here — and it’s dangerous
Ozempic changed everything: Millions of Americans who have discovered the transformative power of one peptide are chasing their next fix Ozempic changed everything: Millions of Americans who have discovered the transformative power of one peptide are chasing their next fix
STAT+: Is the White House’s deal with pharma on GLP-1 drugs a game changer? STAT+: Is the White House’s deal with pharma on GLP-1 drugs a game changer?
President Trump last week hailed his deal with pharma companies to cut the price of blockbuster weight loss drugs as a major win for his administration and for increasing drug affordability. The question is how big of a difference the agreement will make for patients. The deal is expected to significantly expand access to GLP-1 Read More
Gordon Ramsay calls Ozempic restaurant menus ‘absolute bulls—‘ in profanity-filled rantGordon Ramsay calls Ozempic restaurant menus ‘absolute bulls—‘ in profanity-filled rant
Gordon Ramsay didn’t hold back when speaking out on whether he would alter his restaurants’ menus to cater to diners who are taking popular weight loss drugs including Ozempic and Mounjaro. During a recent interview with The Sunday Times, the 59-year-old celebrity chef was asked whether he would create special, smaller-portion menus for patrons using Read More
America’s obesity crisis meets the Ozempic boom as data reveals GLP-1 hot spotsAmerica’s obesity crisis meets the Ozempic boom as data reveals GLP-1 hot spots
With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher — a trend already spreading unevenly across the U.S., with some states seeing greater uptick than others. Based on insurance claims data from Purple Lab, a Read More
Novel GLP-1 Drug on Attack Path Against Very High TriglyceridesNovel GLP-1 Drug on Attack Path Against Very High Triglycerides
(MedPage Today) — NEW ORLEANS — An investigational triple-receptor agonist made some headway in patients with severe hypertriglyceridemia, a phase II study showed. One Chinese cohort had triglycerides slashed from around 800 mg/dL at baseline… (MedPage Today) — NEW ORLEANS — An investigational triple-receptor agonist made some headway in patients with severe hypertriglyceridemia, a Read More
GLP-1 Use Prior to Pregnancy Tied to Lower Gestational Diabetes RiskGLP-1 Use Prior to Pregnancy Tied to Lower Gestational Diabetes Risk
(MedPage Today) — ATLANTA — Women who had been taking GLP-1 receptor agonist medications prior to becoming pregnant had a lower risk of gestational diabetes but not pre-eclampsia during pregnancy, according to a small retrospective cohort study… (MedPage Today) — ATLANTA — Women who had been taking GLP-1 receptor agonist medications prior to becoming Read More
Davina McCall reveals she has undergone surgery for breast cancerDavina McCall reveals she has undergone surgery for breast cancer
Presenter says she is ‘in a much more positive place’ after having lumpectomy and catching cancer earlyDavina McCall has revealed she has undergone surgery for breast cancer and urged others to “get checked”.In a video posted to Instagram, the presenter said she was “very angry” when she found out about the cancer, but felt in a “much more positive place” after a lumpectomy. Continue reading…
HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer modelHER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model
A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses—including histologic cures—with minimal toxicities, paving the way for a safer and more effective treatment option for breast cancer patients.